These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38898061)

  • 1. Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts.
    Nocquet L; Roul J; Lefebvre CC; Duarte L; Campone M; Juin PP; Souazé F
    Sci Rep; 2024 Jun; 14(1):14177. PubMed ID: 38898061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
    Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
    Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
    Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
    Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy.
    Broad RV; Jones SJ; Teske MC; Wastall LM; Hanby AM; Thorne JL; Hughes TA
    Br J Cancer; 2021 Mar; 124(6):1110-1120. PubMed ID: 33398063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
    Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
    Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
    Zoeller JJ; Vagodny A; Daniels VW; Taneja K; Tan BY; DeRose YS; Fujita M; Welm AL; Letai A; Leverson JD; Blot V; Bronson RT; Dillon DA; Brugge JS
    Breast Cancer Res; 2020 Nov; 22(1):132. PubMed ID: 33256808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins.
    Alcon C; Gómez Tejeda Zañudo J; Albert R; Wagle N; Scaltriti M; Letai A; Samitier J; Montero J
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A direct comparison of selective BH3-mimetics reveals BCL-X
    Bierbrauer A; Jacob M; Vogler M; Fulda S
    Br J Cancer; 2020 May; 122(10):1544-1551. PubMed ID: 32203216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.
    Wang B; Ni Z; Dai X; Qin L; Li X; Xu L; Lian J; He F
    Mol Cancer; 2014 Apr; 13():98. PubMed ID: 24779770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
    Eichhorn JM; Alford SE; Sakurikar N; Chambers TC
    Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells.
    Vera MB; Morris-Hanon O; Nogueiras GI; Ripari LB; Esquivel MI; Perez-Castro C; Romorini L; Sevlever GE; Scassa ME; Videla-Richardson GA
    Sci Rep; 2022 Oct; 12(1):17729. PubMed ID: 36273072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro.
    Koehler BC; Scherr AL; Lorenz S; Urbanik T; Kautz N; Elssner C; Welte S; Bermejo JL; Jäger D; Schulze-Bergkamen H
    PLoS One; 2013; 8(10):e76446. PubMed ID: 24098503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells.
    Gayle SS; Sahni JM; Webb BM; Weber-Bonk KL; Shively MS; Spina R; Bar EE; Summers MK; Keri RA
    J Biol Chem; 2019 Jan; 294(3):875-886. PubMed ID: 30482844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
    BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells.
    Das CK; Linder B; Bonn F; Rothweiler F; Dikic I; Michaelis M; Cinatl J; Mandal M; Kögel D
    Neoplasia; 2018 Mar; 20(3):263-279. PubMed ID: 29462756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators.
    Castellanet O; Ahmad F; Vinik Y; Mills GB; Habermann B; Borg JP; Lev S; Lamballe F; Maina F
    Theranostics; 2021; 11(19):9180-9197. PubMed ID: 34646365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
    Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
    Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-xL inhibition radiosensitizes
    Pesch AM; Chandler BC; Michmerhuizen AR; Carter HM; Hirsh NH; Wilder-Romans K; Liu M; Ward T; Ritter CL; Nino CA; Jungles KM; Pierce LJ; Rae JM; Speers CW
    Cancer Res Commun; 2022 Jul; 2(7):679-693. PubMed ID: 36381235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.